ID26679A - BENTUK KRISTAL BARU DARI 6-HIDROKSI-3-(4-(2-(PIPERIDIN-1-IL) ETOKSI) FENOKSI)-2(4-METOKSIFENIL) BENSO (b) TIOFEN HIDROKLORIDA - Google Patents

BENTUK KRISTAL BARU DARI 6-HIDROKSI-3-(4-(2-(PIPERIDIN-1-IL) ETOKSI) FENOKSI)-2(4-METOKSIFENIL) BENSO (b) TIOFEN HIDROKLORIDA

Info

Publication number
ID26679A
ID26679A IDP20000630A ID20000630A ID26679A ID 26679 A ID26679 A ID 26679A ID P20000630 A IDP20000630 A ID P20000630A ID 20000630 A ID20000630 A ID 20000630A ID 26679 A ID26679 A ID 26679A
Authority
ID
Indonesia
Prior art keywords
phenoxices
methodyphenyl
hydroxlorida
ethocysi
tiofen
Prior art date
Application number
IDP20000630A
Other languages
English (en)
Indonesian (id)
Inventor
Julie Kay Bush
Preston Charles Conrad
Meryln Gerard Flom
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ID26679A publication Critical patent/ID26679A/id

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/64—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
IDP20000630A 1999-07-29 2000-07-24 BENTUK KRISTAL BARU DARI 6-HIDROKSI-3-(4-(2-(PIPERIDIN-1-IL) ETOKSI) FENOKSI)-2(4-METOKSIFENIL) BENSO (b) TIOFEN HIDROKLORIDA ID26679A (id)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14618499P 1999-07-29 1999-07-29
US14764299P 1999-08-06 1999-08-06
US14982099P 1999-08-19 1999-08-19

Publications (1)

Publication Number Publication Date
ID26679A true ID26679A (id) 2001-02-01

Family

ID=27386367

Family Applications (1)

Application Number Title Priority Date Filing Date
IDP20000630A ID26679A (id) 1999-07-29 2000-07-24 BENTUK KRISTAL BARU DARI 6-HIDROKSI-3-(4-(2-(PIPERIDIN-1-IL) ETOKSI) FENOKSI)-2(4-METOKSIFENIL) BENSO (b) TIOFEN HIDROKLORIDA

Country Status (44)

Country Link
EP (1) EP1204655B1 (de)
JP (1) JP2001048880A (de)
KR (1) KR100733094B1 (de)
CN (1) CN1138771C (de)
AR (1) AR029176A1 (de)
AT (2) ATE251151T1 (de)
AU (2) AU6335500A (de)
BE (1) BE1013410A3 (de)
BR (1) BR0003211A (de)
CA (1) CA2314685C (de)
CO (1) CO5180572A1 (de)
CZ (1) CZ300356B6 (de)
DE (2) DE60005693T2 (de)
DK (1) DK176771B1 (de)
EG (1) EG24196A (de)
ES (1) ES2208384T3 (de)
FI (1) FI20001721L (de)
FR (1) FR2798384B1 (de)
GB (1) GB2352716A (de)
GR (1) GR20000100264A (de)
HR (1) HRP20000502B1 (de)
HU (1) HUP0003005A2 (de)
ID (1) ID26679A (de)
IL (1) IL137552A (de)
IT (1) IT1318659B1 (de)
LT (1) LT4789B (de)
LU (1) LU90616B1 (de)
LV (1) LV12733B (de)
MD (1) MD2335G2 (de)
MX (1) MXPA00007462A (de)
MY (1) MY120393A (de)
NL (1) NL1015822C2 (de)
NO (1) NO325594B1 (de)
NZ (1) NZ506045A (de)
PE (1) PE20010383A1 (de)
PL (1) PL341748A1 (de)
PT (1) PT102501A (de)
SE (1) SE0002793L (de)
SG (1) SG90737A1 (de)
SI (1) SI20427B (de)
SV (1) SV2002000134A (de)
TR (1) TR200002205A2 (de)
TW (1) TWI271403B (de)
WO (1) WO2001009115A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL365472A1 (en) * 2000-05-08 2005-01-10 Eli Lilly And Company Stabilized formulations of 6-hydroxy-3-(4-[2-(piperidin-1-yl) ethoxy]phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene and salts thereof
US7122203B2 (en) 2000-05-08 2006-10-17 Eli Lilly And Company Stabilized formulations of 6-hydroxy-3-(-4-[2-(piperidin-1-yl) ethoxy]phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene and salts thereof
AU2005200809B2 (en) * 2000-05-08 2006-05-11 Eli Lilly And Company Stabilized Formulations of 6-hydroxy-3-(4-[2-(piperidin-1-yl) Ethoxy]phenoxy)-2-(4-methoxyphenyl) Benzo[b]thiophene and Salts Thereof
EP1757291A3 (de) * 2000-05-08 2009-07-15 Eli Lilly & Company Stabilisierte Formulierungen von 6-Hydroxy-3-(4-[2-(Piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophen und deren Salze
JP2004512333A (ja) * 2000-10-20 2004-04-22 イーライ・リリー・アンド・カンパニー 新規な結晶形の６−ヒドロキシ−３−（４−［２−（ピペリジン−１−イル）エトキシ］フェノキシ）−２−（４−メトキシフェニル）ベンゾ［ｂ］チオフェン塩酸塩
AU2002230409A1 (en) 2000-11-27 2002-06-03 Eli Lilly And Company Process for preparing 3-aryl-benzo(b)thiophenes
EP2233482A1 (de) * 2004-07-22 2010-09-29 Eli Lilly And Company Kristallinvariablenhydrat aus (S)-6-(4-(2-((3-(9H-carbazol-4-yloxy)-2-hydroxypropyl)amino)-2-methylpropyl)phenoxy)-3-pyridincarboxamid-Hemisuccinatsalz
US20060142186A1 (en) * 2004-12-23 2006-06-29 Voyager Pharmaceutical Corporation Leuprolide acetate and acetylcholinesterase inhibitors or NMDA receptor antagonists for the treatment of alzheimer's disease
EP1853263A1 (de) * 2005-02-11 2007-11-14 Eli Lilly And Company Zusammensetzungen und verfahren zur behandlung von dyslipidämie
DE102008057230A1 (de) * 2008-11-11 2010-05-12 Bayer Schering Pharma Aktiengesellschaft Synergistische pharmazeutische Kombination mit einem Estrogenrezeptorantagonisten und einem Progestin
CN113325183B (zh) * 2021-06-01 2022-11-15 中国医学科学院北京协和医院 一种用于鉴别诊断em/fem的试剂盒

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5510357A (en) * 1995-02-28 1996-04-23 Eli Lilly And Company Benzothiophene compounds as anti-estrogenic agents
SG64896A1 (en) * 1995-02-28 1999-05-25 Lilly Co Eli Benzothiophene compounds intermediates compositions and methods
ZA982877B (en) * 1997-04-09 1999-10-04 Lilly Co Eli Treatment of central nervous system disorders with selective estrogen receptor modulators.
AU6335600A (en) * 1999-07-29 2001-02-19 Eli Lilly And Company A novel crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-metho yphenyl)benzo[b]thiophene hydrochloride

Also Published As

Publication number Publication date
CA2314685A1 (en) 2001-01-29
FR2798384A1 (fr) 2001-03-16
PE20010383A1 (es) 2001-04-05
CN1138771C (zh) 2004-02-18
EP1204655A2 (de) 2002-05-15
DK176771B1 (da) 2009-08-03
BE1013410A3 (fr) 2001-12-04
HU0003005D0 (en) 2000-10-28
ITMI20001758A1 (it) 2002-01-28
SI20427B (sl) 2009-04-30
SG90737A1 (en) 2002-08-20
EG24196A (en) 2008-10-14
ES2208384T3 (es) 2004-06-16
CZ20002717A3 (en) 2001-05-16
FR2798384B1 (fr) 2004-09-24
AU779559B2 (en) 2005-01-27
AT502317A1 (de) 2007-02-15
LT4789B (lt) 2001-05-25
FI20001721A7 (fi) 2001-01-30
LU90616B1 (fr) 2007-06-08
MXPA00007462A (es) 2002-06-04
IT1318659B1 (it) 2003-08-27
IL137552A0 (en) 2001-07-24
DE10036855A1 (de) 2001-03-22
WO2001009115A2 (en) 2001-02-08
NZ506045A (en) 2002-02-01
SV2002000134A (es) 2002-06-07
EP1204655B1 (de) 2003-10-01
FI20001721L (fi) 2001-01-30
AU4891100A (en) 2001-02-01
SE0002793D0 (sv) 2000-07-28
IE20000604A1 (en) 2001-04-04
IL137552A (en) 2009-06-15
JP2001048880A (ja) 2001-02-20
NL1015822A1 (nl) 2001-01-30
SI20427A (sl) 2001-06-30
CA2314685C (en) 2009-10-20
WO2001009115A3 (en) 2001-08-16
SE0002793L (sv) 2001-01-30
FI20001721A0 (fi) 2000-07-28
BR0003211A (pt) 2001-03-13
KR100733094B1 (ko) 2007-06-27
CO5180572A1 (es) 2002-07-30
ATE251151T1 (de) 2003-10-15
GB0018636D0 (en) 2000-09-13
GR20000100264A (el) 2001-03-30
HRP20000502B1 (en) 2008-04-30
DK200001150A (da) 2001-01-30
NO20003876L (no) 2001-01-30
HRP20000502A2 (en) 2001-06-30
DE60005693D1 (de) 2003-11-06
GB2352716A (en) 2001-02-07
AU6335500A (en) 2001-02-19
MD2335G2 (ro) 2004-06-30
PT102501A (pt) 2001-01-31
NL1015822C2 (nl) 2004-08-04
ITMI20001758A0 (it) 2000-07-28
AR029176A1 (es) 2003-06-18
HUP0003005A2 (hu) 2002-04-29
KR20010049911A (ko) 2001-06-15
TR200002205A2 (tr) 2001-03-21
CZ300356B6 (cs) 2009-04-29
TWI271403B (en) 2007-01-21
LT2000075A (lt) 2001-02-26
MD2335F2 (en) 2003-12-31
DE60005693T2 (de) 2004-07-29
NO20003876D0 (no) 2000-07-28
MY120393A (en) 2005-10-31
MD20000161A (en) 2001-04-30
PL341748A1 (en) 2001-02-12
CN1283622A (zh) 2001-02-14
LV12733B (lv) 2002-02-20
LV12733A (lv) 2001-10-20
NO325594B1 (no) 2008-06-23
HK1034962A1 (en) 2001-11-09

Similar Documents

Publication Publication Date Title
ID26679A (id) BENTUK KRISTAL BARU DARI 6-HIDROKSI-3-(4-(2-(PIPERIDIN-1-IL) ETOKSI) FENOKSI)-2(4-METOKSIFENIL) BENSO (b) TIOFEN HIDROKLORIDA
DK1341779T3 (da) Heterocyklisk sulfonamid-inhibitorer af beta-amyloidproduktion
ID28779A (id) BENTUK-BENTUK KRISTAL DARI EtO2C-CH2-(R)CgL-Aze-Pab-OH
DK1353917T3 (da) Ny fremgangsmåde til syntesen af 5-(4-fluorphenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrol-3-carboxylsyre phenylamid
DK1218372T3 (da) Nye heterocykliske forbindelser, der er anvendelige som reversible inhibitorer af cysteinproteaser
DK1390377T3 (da) Ny krystalform af azithromycin
NO20035766L (no) Aminonikotinatderivater som glukokinase (GLK) modulatorer
CY2009001I2 (el) Νεα μορφη κρυσταλλου του παραγωγου πυρρολιδυλοθειοκαρβαπενεμης
ID27109A (id) Bentuk kristalin baru dari senyawa benzimidazol antiviral
DK1651622T3 (da) Fremgangsmåde til fremstilling af 2-(quinoxalin-5-ylsulfonylamino)-benzamidforbindelser
DE60139267D1 (de) Etektion von licht
DK1411926T3 (da) Integrininhibitorer til behandling af öjensygdomme
DK0903345T3 (da) Krystalform af N-(4-trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid
AR028281A1 (es) Derivados de 2-(arilalquilamino) pirimidona y derivados de 2-(heteroaroarilalquilamino) pirimidona
ATE369319T1 (de) Flüssigkeitskühlung von glasformen
DE60110718D1 (de) Kühlung nichtlinearer optischer vorrichtungen
ID26137A (id) Komposisi farmasi baru dari uridin trifosfat
PT1103545E (pt) 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6-morfolin-4-il-4-o-totil-piridin-3-il)-isobutiramida
NO20033433D0 (no) Fremgangsmåte for fremstilling av 2-(2-pyridylmetyl)sulfinyl- 1H-benzimidasol
ID27078A (id) SUATU BENTUK KRISTAL BARU DARI 6-HIDROKSI-3-(4-[2-(PIPERIDIN-1-IL) ETOKSI] FENOKSI)-2-(4-METOKSI-FENIL) BENZO [b] TIOFEN HIDROKLORIDA
DE60232290D1 (de) Kontrollierte Auflösung von Wirkstoffen
NO983666L (no) Krystallmodifikasjon av et farmas°ytisk middel
DE60205203D1 (de) Verwaltung von OSI-Schicht-3 Datennetzeinheiten
DK1519928T3 (da) Fremgangsmåde til fremstilling af heterocykliske fluoralkenylsulfoner
DE60227828D1 (de) E von schmelzkleber